I recently read a letter published in your paper in which a concerned citizen called on the government and insurance companies to negotiate better drug prices, citing the high cost of medication in ...

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.